● Recruiting

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Condition: Metastatic Lung Cancer · Sponsor: Institut Curie

PhaseNA

Planned participants300

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.

This description comes directly from the study's public registry record.

Talk to the study team

Marie-Emmanuelle Legrier · 01 56 24 56 49 · marieemmanuelle.legrier@curie.fr

Always discuss trial participation with your own doctor first.

Locations (3)

Hopital Ambroise Pare	Boulogne-Billancourt, France	Recruiting
Institut Curie	Paris, France	Recruiting
Institut Curie	Saint-Cloud, France	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04790682